Company Dossier · Health Care
Molina Healthcare
- Russell 1000
- MidCap 400
What Molina Healthcare is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $44.5 billion, up 2.6% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to September 30, 2025: −$0.57 billion.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to September 30, 2025: $0.11 billion.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 31, 2025: $1.00 billion.SEC EDGAR filings (10-K)
- Long-term debt issued in the fiscal year to December 31, 2025: $0.84 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (July 23, 2026): sentiment -0.20 on a −1 to +1 scale (negative), confidence 0.80 of 1.Palanor Discourse
- Guidance in the last 90 days: 1 outlook figure raised, 0 lowered, 2 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 10, 2026): 0 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q2 2026: $3.4 million on the open market.SEC Form 4
- 601 institutional managers reported a position at June 30, 2026 (+74 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 11 (18 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →Company Posture covers S&P 500 companies.
Credit
How these are built →No bond term sheets or tagged debt on file for Molina Healthcare yet.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
In the news
Headlines that name Molina Healthcare, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NeutralMolina Healthcare Inc (MOH) Stock Down 4.4% -- Now Undervalued? GF Score: 81/100
gurufocus.com · via Marketaux · Oct 1, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 20, 2026LobbyingLobbying report (MEHLMAN CONSULTING, INC.)third_quarter 2026 · $0.1 million
- Oct 14, 2026LobbyingLobbying report (MOLINA HEALTHCARE, INC.)third_quarter 2026 · $0.2 million
- Aug 14, 2026LobbyingLobbying report (FORBES-TATE)third_quarter 2026
- Jul 20, 2026LobbyingLobbying report (FORBES-TATE)second_quarter 2026
- Jul 17, 2026LobbyingLobbying report (MEHLMAN CONSULTING, INC.)second_quarter 2026 · $0.1 million
- Jul 16, 2026LobbyingLobbying report (MOLINA HEALTHCARE, INC.)second_quarter 2026 · $0.2 million
- Jun 18, 2026Trademark
- May 11, 20268-KDirector or officer changeItem 5.02
- May 11, 20268-KShareholder vote resultsItem 5.07
- Apr 20, 2026LobbyingLobbying report (MEHLMAN CONSULTING, INC.)first_quarter 2026 · $0.1 million
- Apr 19, 2026LobbyingLobbying report (FORBES-TATE)first_quarter 2026
- Feb 10, 202610-KAnnual report (10-K)0 risk factors added, 0 removed
- Feb 6, 20268-KMaterial agreement signedItem 1.01
- Feb 6, 20268-KMaterial impairmentItem 2.06
- Nov 20, 20258-KMaterial agreement signedItem 1.01
- Aug 12, 20258-KMaterial agreement signedItem 1.01
- May 1, 20258-KDirector or officer changeItem 5.02
- May 1, 20258-KShareholder vote resultsItem 5.07
- Feb 21, 20258-KMaterial agreement signedItem 1.01
- Feb 11, 202510-KAnnual report (10-K)2 risk factors added, 1 removed
- Nov 18, 20248-KMaterial agreement signedItem 1.01
- Feb 13, 202410-KAnnual report (10-K)38 risk factors added, 10 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Humana HUM | $137B | $1.3B | Mar 31, 2026 |
| Centene Corporation CNC | $179B | $8.9B | Jun 30, 2026 |
| Elevance Health ELV | $201B | $6.3B | Jun 30, 2026 |
| Abbott Laboratories ABT | $45.1B | $7.4B | Mar 31, 2026 |
| Thermo Fisher Scientific TMO | $46.3B | $7.3B | Jun 27, 2026 |
| Bristol Myers Squibb BMY | $49.2B | $11.4B | Jun 30, 2026 |
| Amgen AMGN | $38.1B | $10.2B | Jun 30, 2026 |
| Medtronic MDT | $37.5B | $6.1B | Jul 31, 2026 |